Modulation of excitatory neurotransmission by neuronal/glial signalling molecules: interplay between purinergic and glutamatergic systems
Glutamate is the main excitatory neurotransmitter of the central nervous system (CNS),
released both from neurons and glial cells. Acting via ionotropic (NMDA, AMPA, kainate) and …
released both from neurons and glial cells. Acting via ionotropic (NMDA, AMPA, kainate) and …
[HTML][HTML] The role of P2X7 receptors in a rodent PCP-induced schizophrenia model
B Koványi, C Csölle, S Calovi, A Hanuska, E Kató… - Scientific Reports, 2016 - nature.com
P2X7 receptors (P2X7Rs) are ligand-gated ion channels sensitive to extracellular ATP. Here
we examined for the first time the role of P2X7R in an animal model of schizophrenia. Using …
we examined for the first time the role of P2X7R in an animal model of schizophrenia. Using …
A new potent analgesic agent with reduced liability to produce morphine tolerance
The therapeutic use of opioids is limited by the development of tolerance to the analgesic
effect and the cellular and molecular mechanisms underlying this phenomenon are still not …
effect and the cellular and molecular mechanisms underlying this phenomenon are still not …
Some operational characteristics of glycine release in rat retina: the role of reverse mode operation of glycine transporter type-1 (GlyT-1) in ischemic conditions
A Hanuska, G Szénási, M Albert, L Koles, A Varga… - Neurochemical …, 2016 - Springer
Rat posterior eyecups containing the retina were prepared, loaded with [ 3 H]glycine and
superfused in order to determine its release originated from glycinergic amacrine cells and/or …
superfused in order to determine its release originated from glycinergic amacrine cells and/or …
Role of favipiravir in the treatment of adult patients with moderate to severe COVID-19: a single-center, prospective, observational, sequential cohort study from …
…, E Banyasz, J Budai, E Czel, K Fried, A Hanuska… - medRxiv, 2020 - medrxiv.org
Background Preliminary data suggests that favipiravir might have a role in COVID-19 treatment.
Our aim was to assess the role of favipiravir in the treatment of COVID-19. Methods A …
Our aim was to assess the role of favipiravir in the treatment of COVID-19. Methods A …
[HTML][HTML] Role of favipiravir in the treatment of adult patients with moderate to severe COVID2 19: a single-center, prospective, observational, sequential cohort study …
…, J BUDAI, E CZEL, K FRIED, A HANUSKA… - 2020 - europepmc.org
Background: Preliminary data suggests that favipiravir might have a role in COVID-19 treatment.
Our aim was to assess the role of favipiravir in the treatment of COVID-19. Methods: A …
Our aim was to assess the role of favipiravir in the treatment of COVID-19. Methods: A …
[HTML][HTML] Favipiravir treatment does not influence disease progression among adult patients hospitalized with moderate-to-severe COVID-19: a prospective, sequential …
Data suggests that favipiravir (FVP) could be used against SARS-CoV-2. Our aim was to
investigate the role of FVP in COVID-19 treatment. A prospective sequential cohort study was …
investigate the role of FVP in COVID-19 treatment. A prospective sequential cohort study was …
[HTML][HTML] Clinical and Microbiological Outcomes and Follow-Up of Secondary Bacterial and Fungal Infections among Critically Ill COVID-19 Adult Patients Treated with …
BG Szabó, E Czél, I Nagy, D Korózs, B Petrik, B Marosi… - Antibiotics, 2023 - mdpi.com
Background: Nearly 10% of COVID-19 cases will require admission to the intensive care
unit (ICU). Our aim was to assess the clinical and microbiological outcomes of secondary …
unit (ICU). Our aim was to assess the clinical and microbiological outcomes of secondary …
[HTML][HTML] Outcomes of high-risk adult outpatients with haematological malignancies treated with early remdesivir therapy during the SARS-CoV-2 omicron era …
Z GÁSPÁR, S BG, A ÁBRAHÁM, Z VÁRNAI… - 2022 - europepmc.org
Objectives: Emerging evidence suggests that remdesivir might improve clinical outcome of
high-risk outpatients with COVID-19. Our aim was to evaluate characteristics and outcomes of …
high-risk outpatients with COVID-19. Our aim was to evaluate characteristics and outcomes of …
[HTML][HTML] Baricitinib vs tocilizumab treatment for hospitalized adult patients with severe COVID-19 and associated cytokine storm: a prospective, investigational, real …
B Lakatos, BG Szabó, I Bobek, N Kiss-Dala… - International Journal of …, 2022 - Elsevier
Objectives Our aim was to compare outcomes of hospitalized adults with severe COVID-19
and cytokine storm treated with tocilizumab or baricitinib. Methods A prospective, …
and cytokine storm treated with tocilizumab or baricitinib. Methods A prospective, …